A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naive HIV-1-infected Participants
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Dolutegravir (Primary) ; Lamivudine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science.
- 10 Jun 2017 Biomarkers information updated
- 03 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Oct 2017.